Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab for ulcerative colitis with minimal symptoms but active endoscopic inflammation
jRCT1051210145Active, not recruiting
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of vedolizumab in autoimmune colitis. Primary endpoint: Clinical relapse rate at 54 weeks. Started May 2022; status: active, not recruiting.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT1051210145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051210145.